ATE220896T1 - Hydrogelformulierung mit gesteuerter freisetzung - Google Patents

Hydrogelformulierung mit gesteuerter freisetzung

Info

Publication number
ATE220896T1
ATE220896T1 AT95908570T AT95908570T ATE220896T1 AT E220896 T1 ATE220896 T1 AT E220896T1 AT 95908570 T AT95908570 T AT 95908570T AT 95908570 T AT95908570 T AT 95908570T AT E220896 T1 ATE220896 T1 AT E220896T1
Authority
AT
Austria
Prior art keywords
controlled release
hydrogel formulation
release hydrogel
hydrogel
drug
Prior art date
Application number
AT95908570T
Other languages
English (en)
Inventor
Chih-Ming Chen
Charles S L Chiao
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22721188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE220896(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE220896T1 publication Critical patent/ATE220896T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95908570T 1994-02-14 1995-01-18 Hydrogelformulierung mit gesteuerter freisetzung ATE220896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,377 US5419917A (en) 1994-02-14 1994-02-14 Controlled release hydrogel formulation
PCT/US1995/000717 WO1995021607A1 (en) 1994-02-14 1995-01-18 Controlled release hydrogel formulation

Publications (1)

Publication Number Publication Date
ATE220896T1 true ATE220896T1 (de) 2002-08-15

Family

ID=22721188

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908570T ATE220896T1 (de) 1994-02-14 1995-01-18 Hydrogelformulierung mit gesteuerter freisetzung

Country Status (10)

Country Link
US (1) US5419917A (de)
EP (1) EP0744942B1 (de)
JP (1) JPH10500658A (de)
AT (1) ATE220896T1 (de)
AU (1) AU680112B2 (de)
CA (1) CA2182587A1 (de)
DE (1) DE69527509T2 (de)
NZ (1) NZ279648A (de)
TW (1) TW340045B (de)
WO (1) WO1995021607A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911216B1 (en) 1994-10-12 2005-06-28 Genzyme Corporation Targeted delivery via biodegradable polymers
ATE306903T1 (de) * 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU2068797A (en) * 1996-01-29 1997-08-20 Edward Mendell Co. Inc. Sustained release excipient
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
JP4221068B2 (ja) * 1997-12-17 2009-02-12 興和創薬株式会社 テオフィリン徐放性錠剤及びその製造方法
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
JP4533531B2 (ja) * 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
JP2002531491A (ja) 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (de) * 2001-09-21 2004-06-23 Egalet A/S Polymeres freigabungssystem mit morphin
EP1429802B1 (de) * 2001-09-28 2012-11-07 TNTGamble, Inc. System zur abgabe eines biologischen bestandteiles
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
EP1443910A1 (de) * 2001-11-02 2004-08-11 Wockhardt Limited Zubereitungen mit kontrollierter freigabe von makrolidantibiotika
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
ATE319434T1 (de) * 2001-11-19 2006-03-15 Lupin Ltd Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam- antibiotikums
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
EP1562552A1 (de) * 2002-11-08 2005-08-17 Egalet A/S Zusammensetzung zur kontrollierten wirkstoffabgabe von carvedilol
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
AU2008261957A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
PL2155169T3 (pl) * 2007-06-08 2016-09-30 Formulacja newirapiny o przedłużonym uwalnianiu
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
WO2015073736A1 (en) 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
CA2941829C (en) * 2014-03-11 2021-11-02 Redhill Biopharma Ltd Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220152A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4220153A (en) * 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4894233A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for decongestants
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US5073380A (en) * 1987-07-27 1991-12-17 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
EP0484106A1 (de) * 1990-11-01 1992-05-06 Merck & Co. Inc. Geregelte Verabreichungszusammensetzungen
JPH04316515A (ja) * 1991-04-12 1992-11-06 Shin Etsu Chem Co Ltd 徐放性錠剤
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed

Also Published As

Publication number Publication date
EP0744942A4 (de) 1997-11-12
DE69527509D1 (de) 2002-08-29
US5419917A (en) 1995-05-30
TW340045B (en) 1998-09-11
AU1683695A (en) 1995-08-29
EP0744942B1 (de) 2002-07-24
AU680112B2 (en) 1997-07-17
EP0744942A1 (de) 1996-12-04
NZ279648A (en) 1997-06-24
JPH10500658A (ja) 1998-01-20
WO1995021607A1 (en) 1995-08-17
CA2182587A1 (en) 1995-08-17
DE69527509T2 (de) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE220896T1 (de) Hydrogelformulierung mit gesteuerter freisetzung
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BG102200A (en) Transcorneal system for the release of a medicament
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AU3990797A (en) Sustained release formulation
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
NO20031018D0 (no) Oksymorfonpreparater med kontrollert frigivelse
DK0810856T3 (da) Med bånd forsynet doseringsform af aktivt middel med forlænget frigivelse
ES2105218T3 (es) Composiciones estabilizadoras para dentaduras postizas.
DE59408643D1 (de) Transdermale therapeutische systeme zur verabreichung von serotoninagonisten
ZA963743B (en) Transdermal therapeutic system (TTS) for the administration of testosterone
UA32598C2 (uk) Спосіб одержання лікарської форми карбамазепіну
NO307364B1 (no) Anvendelse av melatoninderivater
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
ATE233745T1 (de) Arzneistoffe
NO973366L (no) Fremgangsmåte for behandling av multippel sklerose
ES2180643T3 (es) Procedimiento para tratar la disfuncion cognitiva.
MX9606009A (es) Uso de 8,9-deshidroestrona como un antioxidante.
MY124089A (en) Use of cetirizine for preventing the onset of asthma
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
SE9501773D0 (sv) New use
JO2127B1 (en) How to prevent asthma